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Abstract: Biofilms formed by multidrug-resistant bacteria are a major cause of hospital-acquired
infections. Cold atmospheric-pressure plasma (CAP) is attractive for sterilization, especially to disrupt
biofilms formed by multidrug-resistant bacteria. However, the underlying molecular mechanism is
not clear. In this study, CAP effectively reduced the living cells in the biofilms formed by methicillin-
resistant Staphylococcus aureus, and 6 min treatment with CAP reduced the S. aureus cells in biofilms
by 3.5 log10. The treatment with CAP caused the polymerization of SaFtsZ and SaClpP proteins in
the S. aureus cells of the biofilms. In vitro analysis demonstrated that recombinant SaFtsZ lost its
self-assembly capability, and recombinant SaClpP lost its peptidase activity after 2 min of treatment
with CAP. Mass spectrometry showed oxidative modifications of a cluster of peaks differing by 16 Da,
31 Da, 32 Da, 47 Da, 48 Da, 62 Da, and 78 Da, induced by reactive species of CAP. It is speculated that
the oxidative damage to proteins in S. aureus cells was induced by CAP, which contributed to the
reduction of biofilms. This study elucidates the biological effect of CAP on the proteins in bacterial
cells of biofilms and provides a basis for the application of CAP in the disinfection of biofilms.
Keywords: cold atmospheric-pressure plasma; biofilm; oxidative damage; reactive species; methicillin-
resistant Staphylococcus aureus
1. Introduction
Staphylococcus aureus, especially methicillin-resistant S. aureus (MRSA), is one of the
most frequent causes of infections and generally forms biofilms on infected tissues [1–5].
Biofilms formed by aggregated microbial cells are surrounded by a self-produced extra-
cellular polymeric matrix made of proteins, DNA, and polysaccharides and adhere to
surfaces, such as those of living tissues [6,7]. The structure of the biofilm makes the biofilm-
associated bacteria more resistant to the host immune defense system, antibiotics, and other
antimicrobial agents [8,9]. Methicillin-resistant S. aureus, especially the multidrug-resistant
strains, frequently exists in the hospital setting in the form of biofilms [10]. When the
multidrug-resistant bacteria infect patients, they also exist in the wounds or other lesions
in the form of biofilms [5,6]. The reduction of biofilms is critical for the prevention and
treatment of infectious diseases caused by multidrug-resistant bacteria [11]. Therefore, the
inactivation of biofilms formed by multidrug-resistant bacteria is a challenging issue in the
therapy of infectious diseases.
Microorganisms 2021, 9, 1072. https://doi.org/10.3390/microorganisms9051072 https://www.mdpi.com/journal/microorganisms
Microorganisms 2021, 9, 1072 2 of 13
Cold atmospheric-pressure plasma (CAP), known as the fourth state of matter, con-
tains various reactive species, such as H2O2, 1O2, •OH, and •NO, as well as electrons, ions,
and photons. The reactive species of CAP can effectively inactivate microorganisms and
cells, which makes it attractive for a range of biomedical applications, such as sterilization
and cancer treatment [12–17]. Planktonic methicillin-resistant S. aureus was fragile to the
surface discharge plasma of CAP, but methicillin-resistant S. aureus usually exists in the
form of biofilms in the environment [18]. Therefore, the inactivation effect of CAP on
biofilms has been studied further. Xu et al. inactivated approximately 4 log10 S. aureus
biofilms after treatment for 10 min with a He/O2 plasma jet, and Wang et al. inactivated
approximately 0.5 log10 S. aureus cells in biofilms after 30 min of exposure to a N2 plasma
jet [19,20]. Czapka et al. inactivated approximately 2.77 log10 S. aureus biofilms after
treatment with dielectric barrier discharge (DBD) for 300 s [21]. However, the molecular
mechanism in the bacterial cells in biofilms inactivated by CAP is poorly understood.
The filamentous temperature-sensitive Z (FtsZ) and ATP-dependent caseinolytic pro-
tease P subunit (ClpP) are both promising targets for antimicrobial agent development [22–26].
FtsZ is the major cytoskeleton protein of the cell division process in prokaryotes and assem-
bles into short, single-stranded protofilaments with an average length of 120–250 nm in vitro,
and into a ring structure in the middle of bacterial cells [22,27,28]. Mutation of Phe138 (F138A)
causes a decrease in polymerization activity and guanosine triphosphatase (GTPase) activ-
ity [29]. The FtsZ protein is involved in cell division, and the inhibition of FtsZ assembly
inhibits cell division [30,31]. FtsZ is essential in S. aureus and cannot be deleted [32]. FtsZ
is also involved in biofilm formation, as demonstrated by a previous study showing the
upregulation of the FtsZ protein in Aggregatibacter actinomycetemcomitans biofilms versus the
planktonic state [33]. The protease ClpP is highly conserved and widely distributed in bacte-
ria and is considered a regulator of the FtsZ protein [30,34]. The ClpP protease is involved
in stress responses, the virulence of pathogenic bacteria, and antibiotic resistance [35–38].
The deletion or inhibition of ClpP proteases resulted in a decrease in persister S. aureus cells
and affected virulence and stress response [6,39,40]. The crystal structures of ClpP proteases
revealed that the SaClpP tetradecamer, which consisted of two heptameric rings, enclosed a
large chamber containing 14 proteolytic active sites (Ser98-His123-Asp172) [41–43]. According
to the findings of another previous study by our group, CAP can induce oxidative modifica-
tion of peptides consisting of histidine and phenylalanine; therefore, CAP was proposed to
have effects on FtsZ protein and ClpP proteases [44].
In this study, the molecular mechanism of CAP on biofilms was studied. The reactive
species of CAP induced aggregation and inactivation of the FtsZ and ClpP proteins in the
cells of Staphylococcus aureus biofilm. These results suggest that the reactive species induced
protein damage, which contributed to the antibiofilm effects.
2. Materials and Methods
2.1. Biofilm Assay
The culture of S. aureus biofilms was performed as previously described [45]. S. aureus
ATCC33591, a methicillin-resistant strain, was purchased from the American Type Culture
Collection (ATCC). A single S. aureus ATCC33591 colony was grown in 4 mL of tryptic
soy broth (TSB, Oxoid, Hampshire, UK) at 250 rpm at 37 ◦C overnight. The overnight
S. aureus cultures were diluted 1:100 in TSB with 1% glucose. The single-side adhesive
silica films (10 × 10 × 0.5 mm, purchased from Taobao) were attached on the bottom of
wells of 24-well plates, covered with diluted S. aureus, and cultured at 37 ◦C for 3 days
without medium renewal. The medium was carefully removed, and the silica films with
biofilms were gently washed three times with saline solution (0.9% NaCl). Four replicates
of biofilms were used for each treatment condition, and untreated biofilms and the biofilms
treated with helium and 1% synthetic air without applying a voltage were used as control.
After treatment, the biofilms were dispersed in 1 mL of saline in 1.5-mL Eppendorf tubes
by sonication for 1 min and vortexing for 5 min. Serial dilutions of each biofilm were
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performed, and 10 µL of each dilution was spotted onto TSB plates and incubated overnight
at 37 ◦C.
2.2. CAP Device and CAP Treatments
The CAP device was similar to the previous study [45]. The surface discharge struc-
ture of the CAP consisted of a high-voltage plane electrode, a liquid-facing grounded
mesh electrode with a hexagonal shape, and a dielectric layer (made of polytetrafluo-
roethylene) sandwiched between the two electrodes (Figure 1). The surface discharge
plasma (40 mm × 40 mm) was generated when a sinusoidal high voltage with a frequency
of 20 kHz was applied. The applied voltage and discharge current were measured with a
high-voltage probe (Tektronix P6015A, Portland, OR, USA) and a current probe (Pearson
2877, Palo Alto, CA, USA), respectively. The discharge power was obtained by integrating
the applied voltage and discharge current demonstrated by an oscilloscope (Tektronix,
MDO3054, Portland, OR, USA). The discharge power was controlled at approximately
3.2 W (the discharge power density of 0.2 W/cm2) with good mesh-to-mesh homogene-
ity through regulating the applied voltage. The values of the peak-to-peak voltage and
discharge current were approximately 7.44 kV and 40.8 mA, respectively.
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Figure 1. Schematic diagram of the S. aureus biofilms (A) and the protein solutions (B) treated with
the surface discharge of cold at ospheric-press re l s .
S. aureus biofilms on sterilized glass slides (a diameter of 30 mm) or protein solutions
(150 µL) in a Petri dish (a diameter of 15 mm), which was smaller in size than the CAP, were
placed under the CAP, and the air gap between the CAP and the surface of the biofilms
or liquid surfaces was 8 ± 0.2 mm (Figure 1). The CAP treatment system was housed
in a sealed organic glass box, and the gas flow of helium and 1% synthetic air (79% N2
+ 21% O2) flowed into the organic glass box at a constant rate of 4 L/min, controlled by
the mass flow controller (MFC, Sevenstar, Beijing, China), diffused through pores at the
bottom part, and then spread upward to the underneath of the surface plasma. The flow
rate at the outlet was less than 1 L/min measured by a rotameter, which indicated that
most of the gas leaked through the small gaps that were not completely sealed to prevent
the increase in pressure in the chamber (Figure 1). Synthetic air was used as the source
of reactive species, while helium was used to enhance the production efficiency of those
species as well as their flux on the treated samples via diffusion. The ambient temperature
of the gas chamber and the temperature of samples were measured using a thermocouple,
and both the temperatures were lower than 35 ◦C after 6 min of CAP treatment at a room
temperature of 28 ◦C.
A 
Dielectric layer High-voltage electrode 
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2.3. Protein Extraction and Detection
The S. aureus cells from CAP-treated and untreated biofilms were resuspended in
solubilization buffer (50 mM imidazole, 50 mM NaCl, 2 mM 6-aminohexanoic acid, 1 mM
EDTA, and 1% dodecylmaltoside; pH 7.0), and lysis was performed by bead beating in a
MiniBeadbeater-16 (Biospec, Bartlesville, OK, USA). After centrifugation, the supernatants
were transferred, and protein concentrations were determined by the BCA Protein Assay
Kit (Beyotime, Shanghai, China) using bovine serum albumin (BSA) as the standard. The
soluble proteins (10 µg) were mixed with Laemmli buffer (Bio-Rad, Hercules, CA, USA)
and subjected to 15% SDS-PAGE. The gel was stained with Coomassie Brilliant Blue G-250
or transferred to PVDF membranes and subjected to immunoblotting.
2.4. SaFtsZ and SaClpP Protein Expression and Purification
The genes encoding FtsZ (ORF: SACOL1199) and ClpP (ORF: SACOL0833) were am-
plified from the genomic DNA of S. aureus ATCC33591 by PCR using Pfu DNA polymerase
(Stratagene, La Jolla, CA, USA) (for primer sequences, see Table 1). The PCR product
was inserted into the NdeI/XhoI sites of the expression vector pET-28a (for His-tagged
SaFtsZ) or pET-32a (for His-tagged and untagged SaClpP) (Novagen, Darmstadt, Ger-
many). Expression plasmids were transformed into E. coli BL21(DE3) cells. The cells were
grown and induced by the addition of isopropyl-β-D-thiogalactopyranoside (IPTG). For
His-tagged SaFtsZ and SaClpP, the induced cells were suspended in lysis buffer containing
50 mM Tris-Cl (pH 7.5) and 500 mM NaCl and then lysed at 4 ◦C by sonication. After
centrifugation at 16,000× g for 20 min to remove the insoluble material, the supernatant
was loaded onto a Histrap column (1 mL; GE Healthcare, Marlborough, MA, USA), and
the protein was eluted with a single gradient of 0.5 M imidazole in lysis buffer. Fractions
containing SaFtsZ or SaClpP were pooled and dialyzed against 50 mM HEPES (pH 7.5),
5 mM MgCl2, and 100 mM KCl. For untagged SaClpP, the induced cells were suspended
in lysis buffer containing 50 mM Tris-Cl (pH 7.5), 100 mM NaCl, and 1 mM dithiothreitol
(DTT) and lysed at 4 ◦C by sonication. After centrifugation at 16,000× g for 20 min to
remove the insoluble material, the supernatant was loaded onto a Hitrap Capto Q column
(5 mL; GE Healthcare), and the protein was eluted with a single gradient of 1 M NaCl in
lysis buffer. The Q column fractions containing SaClpP were pooled and loaded onto a
Superdex G200 column (24 mL; GE Healthcare, Marlborough, MA, USA) equilibrated with
50 mM Tris-Cl (pH 7.5), 100 mM NaCl, and 1 mM DTT. Fractions containing SaClpP were
pooled and dialyzed against 10 mM Tris-Cl (pH 7.5), 1 mM EDTA, and 1 mM DTT. Protein
concentrations were determined by a BCA Protein Assay Kit (Beyotime, Shanghai, China)
using bovine serum albumin (BSA) as the standard.
Table 1. The primers used in this study.
Designation Sequence (5′-3′)
ftsZ up ATCATGCCATGGTAGAATTTGAACAAGGATTTA
ftsZ His-tag down ATACCGCTCGAGACGTCTTGTTCTTCTTGAACGTC
clpP up ATGGGAATTCCATATGAATTTAATTCCTACAGTTATTGAAAC
clpP His-tag down ATACCGCTCGAGTTTTGTTTCAGGTACCATCACTTC
clpP down ATACCGCTCGAGTTATTTTGTTTCAGGTACCATCACTTC
2.5. Immunoblotting
Anti-SaFtsZ and anti-SaClpP antibodies were raised in rabbits using purified His-
tagged SaFtsZ and SaClpP. The blots were blocked in 5% milk/Tris-buffered saline with
0.5% Tween (TBST) at 4 ◦C overnight with gentle agitation. After incubation with anti-
SaFtsZ or anti-SaClpP antibodies for 2 h at room temperature with gentle agitation, the
blots were washed four times (10 min per wash) with TBST at room temperature. The
blots were incubated with Dylight649 Goat Anti-Rabbit IgG (Abbkine, Wuhan, China)
for 1 h at room temperature with gentle agitation and washed again as described above.
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The blots were detected using a Typhoon FLA9500 biomolecular imager (GE Healthcare,
Marlborough, MA, USA).
2.6. Blue Native Polyacrylamide Gel Electrophoresis
The recombinant SaFtsZ and untagged SaClpP proteins (1 mg/mL) in 10 mM Tris-Cl
(pH 7.5) and 1 mM EDTA were treated with CAP for 2 min, as shown in Figure 1B. The
soluble proteins (20 µg) from the CAP-treated and untreated biofilms were mixed with
4× loading buffer (200 mM imidazole, 200 mM NaCl, 20% glycerol, and 0.02% Ponceau S)
and electrophoresed through a 10–20% (for SaFtsZ) or 4–15% (for SaClpP) gradient blue
native polyacrylamide gel [46]. The gel was stained with Coomassie Brilliant Blue R-250 or
subjected to immunoblotting. The gel for immunoblotting was washed with electroblotting
buffer (25 mM Tris-Cl, pH 7.5, 250 mM glycine, and 0.1% sodium dodecyl sulfate (SDS)) for
30 min and transferred to a PVDF membrane using the electroblotting buffer for 3 h at 4 ◦C
with a current of 150 mA. After transfer, methanol was used to destain the background of
the PVDF membrane. Then, the PVDF membranes were subjected to immunoblotting.
2.7. In Vitro Assembly Assay of SaFtsZ
The SaFtsZ proteins treated with the CAP, treated with the mixture of H2O2 + NO2− +
NO3− (saline with 250 µM H2O2 + 125 µM NO2− + 375 µM NO3−), or left untreated were
incubated with 2 mM guanosine triphosphate (GTP) in HMK buffer (50 mM HEPES-OH,
pH 7.5, 5 mM MgAc, and 100 mM KCl) for 10 min at 37 ◦C. Then, the SaFtsZ proteins
were diluted five times with HMK buffer. For negative staining, an aliquot (~4 µL) of
proteins was dropped onto a glow-discharged thin carbon-coated 200-mesh grid (Carbon
Gilder Finder Grids, Cu, F1 UL) and kept for 1 min at 22 ◦C. Then, the excess solution was
removed by touching a piece of filter paper to the back of the grid. The grid was washed by
briefly touching the surface of the grid with a drop (~30 µL) of deionized water on Parafilm
and then blotted dry with filter paper. The touching and blotting steps were repeated once.
Two successive drops (~25 µL/drop) of 1% (w/v) uranyl acetate (UA) solution were applied
to Parafilm, and the excess solution was removed by blotting similarly. The grid remained
in contact with the last UA drop with the sample side down for 1 min in the dark before
the excess stain was removed, and the sample was air-dried at room temperature. The
stained samples were examined using an FEI Talos F200C transmission electron microscope
operating at 200 kV at 57,000×magnification.
2.8. Enzymatic Activity Assay of SaClpP
Peptidase activity was detected as described previously using the model fluorogenic
substrate dipeptide N-succinyl-Leu-Tyr-7-amido-4-methylcoumarin (Suc-LY-AMC) (MP
Biomedicals, Santa Ana, CA, USA) [47]. The CAP-treated, H2O2 + NO2− + NO3− treated,
or untreated SaClpP (5 µM monomer) was incubated with Suc-LY-AMC (250 µM) in 50 mM
HEPES-OH (pH 7.5) and 100 mM NaCl. The hydrolysis of the labeled peptide led to
the release of fluorescent AMC. The fluorescence was measured on a microplate reader
(Thermo Scientific Varioskan Flash, Waltham, MA, USA) at 37 ◦C for 30 cycles every 60 s
using an excitation wavelength of 340 nm and an emission wavelength of 450 nm, as
described previously [48].
2.9. Mass Spectrometry of SaClpP
The CAP-treated and untreated SaClpP (5 µg) were subjected to SDS-PAGE (15%)
and visualized by staining with Coomassie Brilliant Blue R-250. The protein bands were
excised, and the protein was digested in-gel with trypsin, as described previously [49]. The
digested products were dissolved in 0.1% formic acid and purified with ZipTipC18 pipette
tips (Millipore, Darmstadt, Germany) according to the manufacturer’s procedure. The
tryptic peptides were identified using an Orbitrap Fusion Tribrid mass spectrometer (Ther-
moFisher, Waltham, MA, USA) coupled to an EASY-nLC 1000 UPLC system (ThermoFisher,
Waltham, MA, USA).
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3. Results
3.1. Inactivation of CAP Treatment on Biofilms
The inactivation effect of CAP on S. aureus biofilms was first determined (Figure 2). The
CAP treatment for 2 min decreased the number of living S. aureus cells by approximately
0.5 log10 in biofilms, while that for 4 min decreased them by less than 2 log10. After the
biofilms were treated with CAP for 6 min, the living cells in the biofilms were reduced by
approximately 3.5 log10 in the biofilms. Therefore, CAP treatment can effectively reduce
the living cells in S. aureus biofilms.
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Figure 2. Inactivation effect on S. aureus biofilms of CAP. The biofilms were treated with CAP for
the indicated times, and the CAP-treated and untreated biofilms were dispersed in 1 mL saline by
sonication and vortexing. Serial dilutions of each biofilm were performed, and 10 µL of each dilution
was spotted onto TSB plates and incubated overnight at 37 ◦C. E ror bars represent the standard
deviation (SD).
3.2. CAP Treatment Causes Polymerization of the SaFtsZ and SaClpP and Induces Oxidative
Modification of Proteins
To investigate the molecular mechanisms underlying the inactivation of CAP treat-
ment, the soluble proteins from the CAP-treated and untreated S. aureus biofilms separated
by both SDS-PAGE and blue-native gels and the SaFtsZ and SaClpP proteins were detected
using immunoblotting. The SaFtsZ protein of the untreated biofilms exhibited a single
band, whereas that of the CAP-treated biofilms exhibited two close bands (Figure 3A and
Figure S1). The emerging band migrated slightly more slowly than the main band and
increased with the time of CAP treatment. Then, blue native gels were employed to identify
changes in the SaFtsZ protein. Compared with the SaFtsZ protein of the untreated biofilms,
the SaFtsZ protein of the biofilms treated with the CAP for 1 min started to form larger
polymers, and the SaFtsZ protein of the biofilms treated with the CAP for 3 min formed
larger polymers (Figure 3B). The bands of the SaClpP protein from the biofilms after the
CAP treatment for 1 to 4 min migrated slightly more slowly than those from the untreated
biofilms (Figure 3C). The bands of the SaClpP protein became dispersive and fuzzy in blue
native gels from biofilms treated with the CAP for 1 min compared with untreated biofilms.
The SaClpP protein was hardly detectable after the CAP treatment for 2 min to 4 min,
and the smear of larger polymers became more intense (Figure 3D). These results indicate
that the CAP treatment of S. aureus biofilms caused the polymerization of the SaFtsZ and
SaClpP proteins.
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3.3. CAP Treatment Causes Inactivation of the SaFtsZ and SaClpP Proteins
To analyze the biological effects of the CAP treatment on proteins, the recombinant
SaFtsZ and SaClpP proteins were treated with the CAP. The SaFtsZ and SaClpP proteins
in S. aureus cells were entirely damaged after treatment by CAP for 2 min; therefore, the
treatment time of recombinant proteins was 2 min. Based on the previous study, three
kinds of long-lived reactive species, namely, H2O2, NO2−, and NO3−, were generated in
the same CAP, with concentrations of 53.3 µM, 25.4 µM, and 148.0 µM, respectively [38].
Then, a mixed solution with higher concentrations of H2O2 (100 µM), NO2− (100 µM),
and NO3− (500 µM) was also employed for comparison. After the CAP treatment, the
denatured SaFtsZ protein migrated slightly more slowly than the untreated SaFtsZ protein
(Figure 4A). The untreated SaFtsZ protein was a monomer, and the CAP-treated SaFtsZ
protein formed larger polymers (Figure 4B). To further evaluate the effect on the proteins,
the self-assembling capacity of SaFtsZ protein was analyzed by electron microscopy (EM).
The CAP-treated SaFtsZ protein lost its self-assembly capability, whereas the untreated
SaFtsZ protein self-assembled into protofilaments in the presence of GTP (Figure 4C).
The denatured CAP-treated SaClpP protein migrated more slowly than the untreated
SaClpP protein (Figure 5A). The untreated SaClpP protein exhibited tetradecamers and
heptamers, and the CAP-treated SaClpP protein became a larger smear probably formed
by large polymers (Figure 5B). To further evaluate the effect on proteins, peptidase activity
against peptide substrates was tested. The cleavage of the dipeptide (N-succinyl-Leu-Tyr-
7-amido-4-methylcoumarin) by CAP-treated SaClpP was hardly detectable, suggesting
that the peptidase activity of the SaClpP protein was inactivated by the CAP treatment
(Figure 5C). These results indicated that the CAP treatment caused polymerization and
inactivated the activity of the SaFtsZ and SaClpP proteins in vitro.
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3.4. CAP Induces Oxidative Modification in Proteins
To elucidate the mechanism underlying the effect of the CAP treatment on proteins,
the SaClpP proteins were analyzed by mass spectrometry. The mass weights of untreated
SaClpP proteins were 21,513.17 (theoretical Mr: 21,513.57) and 21,267.09 with two amino
acid deletions of the N-terminus (Figure 6A). The CAP-treated SaClpP appeared to be
modified at multiple sites: a cluster of peaks differing by 16 Da, 31 Da, 32 Da, 47 Da, 48 Da,
62 Da, and 78 Da were detected (Figure 6B). The shifts of 16 Da and 32 Da were consistent
with the hydroxy group (ROH) and the hydroperoxide group (ROOH) or two hydroxy
groups, respectively. The shift of 31 Da corresponded to ROO- or a combination of one RO-
and one hydroxy group, and the shift of 62 Da corresponded to the combination of two
ROO- groups, one RO-OR (+30 Da) group and one hydroperoxide group, or two hydroxy
groups. Mass fingerprinting showed that the SaClpP protein was oxidatively modified at
multiple sites (Table S1 and Figure S2). These results demonstrate that the reactive oxygen
species from the CAP induced oxidative modification of the SaClpP protein.
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4. Discussion
CAP based on the electrical method can efficiently inactivate bacteria and reduce
biofilms. The SaFtsZ and SaClpP proteins could be modified and inactivated by the CAP
treatment in both in vitro and S. aureus cells, which contributed to the reduction of biofilms
by CAP. The understanding of the molecular mechanism of this process is helpful in
optimizing the control of CAP and guiding the application of CAP.
CAP contains various reactive species, such as long-lived H2O2, NO2−, and NO3−
and short-lived •OH, 1O2, •NO, and ONOO−, as previously described [18,44]. The mixture
of three long-lived species, namely, H2O2, NO2−, and NO3−, exhibited little effect on
SaFtsZ and SaClpP proteins, which demonstrated that the short-lived species were critical
in the process. The reactive species penetrated bacterial cells in biofilms and induced
the polymerization of the SaFtsZ and SaClpP proteins. A previous study also found that
CAP-induced polymerization of GFP-tagged proteins caused protein denaturation and
insolubility in Saccharomyces cerevisiae [50]. In this study, the polymerized proteins were in
the soluble fraction, and this effect could be reversed by the reducing agent. These effects
seemed to be similar to the effects of disulfide bond formation, and the reactive oxygen
species could also cause cysteine to form disulfide bonds. However, the SaFtsZ protein
did not contain cysteine, and further mass spectrometry analysis demonstrated that the
oxidative modifications of the SaClpP protein were mainly induced by the CAP treatment.
Therefore, oxidative modifications, such as ROOR, occurred between proteins and caused
protein polymerization. 1O2 and O2•− are both generated by CAP and can rapidly and
selectively react with amino acids, efficiently yielding hydroperoxide groups [44,51–54].
Therefore, the reactive species of CAP reacted with proteins and caused the polymerization
and function loss of proteins through oxidative modifications.
The treatment of CAP exhibited similar effects on the recombinant SaFtsZ and SaClpP
proteins and the SaFtsZ and SaClpP proteins from S. aureus biofilms. However, the in vitro
analysis could not fully reflect the effects in bacterial cells for two reasons. The first reason
is that the reactive species need to cross the cell walls and membranes into the cells and
then react with the proteins in the cells [55,56]. Not all of the reactive species of CAP
could enter into the cells. The second reason is that the reactive species entering into
the cells were affected by the enzymes in the cell or reacted with the reactive species
produced by the cells [57]. The types and amounts of reactive species in the cells would
change. In the in vitro treatment, the reactive species directly reacted with the recombi-
nant proteins without the obstacle of the cell wall and membrane and the effects of the
intracellular enzymes.
It is inevitable that the reactive species of CAP will react with other proteins in S. aureus
cells and cause damage due to the non-selectivity and high reactivity of radical species [52].
Previous studies demonstrated that CAP induced double-stranded and single-stranded
breaks in DNA and crosslinks between DNA and proteins in Escherichia coli cells [44,58].
Therefore, the reactive species of CAP caused oxidative damage on DNA and various
proteins, including SaFtsZ and SaClpP, and the damages synergistically caused the death
of S. aureus cells in the biofilm.
Based on these results, a model of CAP treatment for biofilm eradication was pro-
posed (Figure 7). Reactive oxygen species generated by plasma, such as O2•−, diffused
into biofilms and entered into S. aureus cells. The reactive oxygen species reacted with
proteins, such as SaFtsZ and SaClpP, and induced oxidative modifications that caused
polymerization and functional loss of proteins. Inactivation of SaFtsZ and SaClpP blocked
the growth and division of S. aureus cells, resulting in the death and eradication of biofilms.
Therefore, cold atmospheric-pressure plasma could be developed and used in strategies
for both the disinfection of biofilms and therapy for wound infections.
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